ArticleJournal of nephrology2025
Validation and modification of renal risk score for prediction of long-term kidney survival in patients with MPO-ANCA-associated glomerulonephritis.
Article in Journal of nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundAnti-neutrophil cytoplasmic antibody (ANCA) Renal Risk Score has not been widely validated in Chinese patients with myeloperoxidase -ANCA-associated glomerulonephritis and its predictive ability needs to be improved.
methodsThree hundred and forty patients with biopsy-proven myeloperoxidase-ANCA-associated glomerulonephritis were included in this study. They were divided into an oliguric group (urine volume < 400 ml/24 h) and a non-oliguric group (urine volume ≥ 400 ml/24 h). The ANCA Renal Risk Score and Berden classes were used to predict the risk of end-stage kidney disease (ESKD), and Cox regression analysis was performed to evaluate the impact of oliguria on ESKD risk.
resultsThe predictive performance of ANCA Renal Risk Score was significantly higher than that of Berden classes (AUC: 0.79 vs. 0.709, P = 0.003). Thirty-six (10.6%) patients presented with oliguria. Patients in the oliguric group had significantly lower levels of baseline estimated glomerular filtration rate (eGFR) [6.51(4.55-7.72) vs. 21.22(11.49-36.63) ml/min/1.73 m
conclusionsThis study has validated the ANCA Renal Risk Score for predicting kidney outcomes among Chinese patients with myeloperoxidase-ANCA-associated glomerulonephritis. Furthermore, the ANCA Renal Risk Score-U model with oliguria as a variable can further improve the prediction of ESKD risk in patients with myeloperoxidase-ANCA-associated glomerulonephritis.
Indexed as
Identifiers
39576457What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.